Exposing a deadly alliance: Novel insights into the biological links between COPD and lung cancer

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 5, 2013, Pages 544-554

  Vermaelen, K ^a   Brusselle, G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

COPD; GWAS; Inflammation; Lung cancer; Reactive oxygen species; STAT3

Indexed keywords

ACETYLCHOLINERGIC NICOTINIC RECEPTOR; CARBON MONOXIDE; DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR; GELATINASE B; HEDGEHOG INTERACTING PROTEIN; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; MACROPHAGE ELASTASE; NICOTINIC RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RANTES; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; STAT3 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER MORTALITY; CELL DAMAGE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ASSOCIATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; LANGERHANS CELL; LUNG CANCER; LUNG CARCINOGENESIS; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; MACROPHAGE; MALIGNANT TRANSFORMATION; MULTIPLE TRAUMA; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; REVIEW; SEPSIS; SMOKING; SUPPRESSOR CELL; TUMORASSOCIATED MACROPHAGE;

COPD; GWAS; INFLAMMATION; LUNG CANCER; REACTIVE OXYGEN SPECIES; STAT3;

ANIMALS; ENVIRONMENTAL EXPOSURE; EPIGENESIS, GENETIC; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MASS SCREENING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84882649918     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.05.003     Document Type: Review

References (108)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010, 127(12):2893-2917.
2. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367(9524):1747-1757.
3. Brusselle G.G., Joos G.F., Bracke K.R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011, 378(9795):1015-1026.
4. Celli B.R. Chronic obstructive pulmonary disease and lung cancer. Proceedings of the American Thoracic Society 2012, 9(2):74-79.
5. Mannino D.M., Aguayo S.M., Petty T.L., Redd S.C. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Archives of Internal Medicine 2003, 163(12):1475-1480.
6. Young R.P., Hopkins R.J., Christmas T., Black P.N., Metcalf P., Gamble G.D. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. European Respiratory Journal 2009, 34(2):380-386.
7. Tockman M.S., Anthonisen N.R., Wright E.C., Donithan M.G. Airways obstruction and the risk for lung cancer. Annals of Internal Medicine 1987, 106(4):512-518.
8. Skillrud D.M., Offord K.P., Miller R.D. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Annals of Internal Medicine 1986, 105(4):503-507.
9. Lange P., Nyboe J., Appleyard M., Jensen G., Schnohr P. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. American Journal of Respiratory and Critical Care Medicine 1990, 141(3):613-617.
10. Thomsen M., Dahl M., Lange P., Vestbo J., Nordestgaard B.G. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2012, 186(10):982-988.
11. Wilson D.O., Weissfeld J.L., Balkan A., Schragin J.G., Fuhrman C.R., Fisher S.N., et al. Association of radiographic emphysema and airflow obstruction with lung cancer. American Journal of Respiratory and Critical Care Medicine 2008, 178(7):738-744.
12. de Torres J.P., Marín J.M., Casanova C., Cote C., Carrizo S., Cordoba-Lanus E., et al. Lung cancer in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2011, 184(8):913-919.
13. de Torres J.P., Marin J.M., Casanova C., Cote C., Carrizo S., Cordoba-Lanus E., et al. Lung Cancer in patients with COPD: incidence and predicting factors. American Journal of Respiratory and Critical Care Medicine 2011 Oct 15, 184(8):913-919.
14. Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M., et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370(9589):741-750.
15. Loganathan R.S., Stover D.E., Shi W., Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer*. CHEST Journal 2006, 129(5):1305-1312.
16. Caramori G., Casolari P., Cavallesco G.N., Giuffre S., Adcock I., Papi A. Mechanisms involved in lung cancer development in COPD. The International Journal of Biochemistry & Cell Biology 2011, 43(7):1030-1044.
17. Rooney C., Sethi T. The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer. Respiration; International Review of Thoracic Diseases 2011, 81(2):89-104.
18. Prevot G., Plat G., Mazieres J. COPD and lung cancer: epidemiological and biological links. Revue des maladies respiratoires 2012, 29(4):545-556.
19. Vakkila J., Lotze M.T. Inflammation and necrosis promote tumour growth. Nature Reviews Immunology 2004, 4(8):641-648.
20. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
21. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
22. Ferguson L.R. Chronic inflammation and mutagenesis. Mutation Research 2010, 690(1-2):3-11.
23. Dixon K., Kopras E. Genetic alterations and DNA repair in human carcinogenesis. Seminars in Cancer Biology 2004, 14(6):441-448.
24. Caramori G., Adcock I.M., Casolari P., Ito K., Jazrawi E., Tsaprouni L., et al. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax 2011, 10.1136/thx.2010.156448.
25. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Seminars in Cancer Biology 2006, 16(1):38-52.
26. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology 2012, 12(4):253-268.
27. Cuenca A.G., Delano M.J., Kelly-Scumpia K.M., Moreno C., Scumpia P.O., Laface D.M., et al. Aparadoxical role for myeloid-derived suppressor cells in sepsis and trauma. Molecular Medicine 2011, 17(3-4):281-292.
28. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Natural Medicines 2007, 13(7):828-835.
29. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Seminars in Cancer Biology 2008, 18(5):349-355.
30. Gutierrez P., Closa D., Piner R., Bulbena O., Menendez R., Torres A. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 2010, 36(2):285-291.
31. Shaykhiev R., Krause A., Salit J., Strulovici-Barel Y., Harvey B.G., O'Connor T.P., et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. Journal of Immunology 2009, 183(4):2867-2883.
32. Modi B.G., Neustadter J., Binda E., Lewis J., Filler R.B., Roberts S.J., et al. Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science 2012, 335(6064):104-108.
33. Van Pottelberge G.R., Bracke K.R., Demedts I.K., De Rijck K., Reinartz S.M., vanDrunen C.M., et al. Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD. Respiratory Research 2010, 11:35.
34. Ochoa C.E., Mirabolfathinejad S.G., Ruiz V.A., Evans S.E., Gagea M., Evans C.M., et al. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prevention Research 2011, 4(1):51-64.
35. Moghaddam S.J., Ochoa C.E., Sethi S., Dickey B.F. Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer. International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:113-123.
36. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology 2007, 7(1):41-51.
37. Niu G., Briggs J., Deng J., Ma Y., Lee H., Kortylewski M., et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res. 2008, 6(7):1099-1105.
38. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009, 15(2):79-80.
39. Qu P., Roberts J., Li Y., Albrecht M., Cummings O.W., Eble J.N., et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 2009, 63(3):341-347.
40. Young R.P., Hopkins R.J. How the genetics of lung cancer may overlap with COPD. Respirology 2011, 16(7):1047-1055.
41. Li Y., Du H., Qin Y., Roberts J., Cummings O.W., Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Research 2007, 67(18):8494-8503.
42. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441(7092):431-436.
43. Di Stefano A., Caramori G., Oates T., Capelli A., Lusuardi M., Gnemmi I., et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 2002, 20(3):556-563.
44. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15(4):283-293.
45. Bracke K., Cataldo D., Maes T., Gueders M., Noël A., Foidart J.-M., et al. Matrix metalloproteinase-12 and cathepsin D expression in pulmonary macrophages and dendritic cells of cigarette smoke-exposed mice. International Archives of Allergy and Applied Immunology 2005, 138(2):169-179.
46. Molet S., Belleguic C., Lena H., Germain N., Bertrand C.P., Shapiro S.D., et al. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflammation Research: Official Journal of the European Histamine Research Society [etal] 2005, 54(1):31-36.
47. Hautamaki R.D., Kobayashi D.K., Senior R.M., Shapiro S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277(5334):2002-2004.
48. Houghton A.M., Quintero P.A., Perkins D.L., Kobayashi D.K., Kelley D.G., Marconcini L.A., et al. Elastin fragments drive disease progression in a murine model of emphysema. The Journal of Clinical Investigation 2006, 116(3):753-759.
49. de Torres J.P., Bastarrika G., Wisnivesky J.P., Alcaide A.B., Campo A., Seijo L.M., et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007, 132(6):1932-1938.
50. Vernooy J.H.J., Lindeman J.H.N., Jacobs J.A., Hanemaaijer R., Wouters E.F.M. Increased activity of matrix Metalloproteinase-8 and matrix Metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004, 126(6):1802-1810. 10.1378/chest.126.6.1802.
51. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2(10):737-744.
52. Cho M.H., Boutaoui N., Klanderman B.J., Sylvia J.S., Ziniti J.P., Hersh C.P., et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nature Genetics 2010, 42(3):200-202.
53. Hancock D.B., Eijgelsheim M., Wilk J.B., Gharib S.A., Loehr L.R., Marciante K.D., et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nature Genetics 2010, 42(1):45-52.
54. Amos C.I., Wu X., Broderick P., Gorlov I.P., Gu J., Eisen T., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genetics 2008, 40(5):616-622.
55. Ben J., Jin G., Zhang Y., Ma B., Bai H., Chen J., et al. Class a scavenger receptor deficiency exacerbates lung tumorigenesis by cultivating a procarcinogenic microenvironment in humans and mice. American Journal of Respiratory and Critical Care Medicine 2012, 186(8):763-772.
56. Landi M.T., Chatterjee N., Yu K., Goldin L.R., Goldstein A.M., Rotunno M., et al. Agenome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. The American Journal of Human Genetics 2009, 85(5):679-691.
57. McKay J.D., Hung R.J., Gaborieau V., Boffetta P., Chabrier A., Byrnes G., et al. Lung cancer susceptibility locus at 5p15.33. Nature Genetics 2008, 40(12):1404-1406.
58. Ohar J.A., Hamilton J.R.F., Zheng S., Sadeghnejad A., Sterling D.A., Xu J., et al. COPD is associated with a macrophage scavenger Receptor-1 gene sequence variation. CHEST Journal 2010, 137(5):1098-1107.
59. Pillai S.G., Ge D., Zhu G., Kong X., Shianna K.V., Need A.C., et al. Agenome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLos Genetics 2009, 5(3):e1000421.
60. Repapi E., Sayers I., Wain L.V., Burton P.R., Johnson T., Obeidat M., et al. Genome-wide association study identifies five loci associated with lung function. Nature Genetics 2010, 42(1):36-44.
61. Shi W., Bellusci S., Warburton D. Lung development and adult lung diseases. Chest 2007, 132(2):651-656.
62. Van Durme Y.M., Eijgelsheim M., Joos G.F., Hofman A., Uitterlinden A.G., Brusselle G.G., et al. Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. European Respiratory Journal 2010, 36(1):89-95.
63. Wang Y., Broderick P., Webb E., Wu X., Vijayakrishnan J., Matakidou A., et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nature Genetics 2008, 40(12):1407-1409.
64. Watkins D.N., Berman D.M., Burkholder S.G., Wang B., Beachy P.A., Baylin S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422(6929):313-317.
65. Wauters E., Smeets D., Coolen J., Verschakelen J., De Leyn P., Decramer M., et al. The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 2011, 38(4):924-931.
66. Wilk J.B., Chen T.H., Gottlieb D.J., Walter R.E., Nagle M.W., Brandler B.J., et al. Agenome-wide association study of pulmonary function measures in the Framingham Heart Study. PLos Genetics 2009, 5(3):e1000429.
67. Young R.P., Hopkins R.J., Whittington C.F., Hay B.A., Epton M.J., Gamble G.D. Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD. PloS One 2011, 6(2):e16476.
68. Young R.P., Whittington C.F., Hopkins R.J., Hay B.A., Epton M.J., Black P.N., et al. Chromosome 4q31 locus in COPD is also associated with lung cancer. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 2010, 36(6):1375-1382.
69. Young R.P., Hopkins R.J., Hay B.A., Epton M.J., Black P.N., Gamble G.D. Lung cancer gene associated with COPD: triple whammy or possible confounding effect?. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 2008, 32(5):1158-1164.
70. Bierut L.J., Stitzel J.A., Wang J.C., Hinrichs A.L., Grucza R.A., Xuei X., et al. Variants in nicotinic receptors and risk for nicotine dependence. The American Journal of Psychiatry 2008, 165(9):1163-1171.
71. West K.A., Brognard J., Clark A.S., Linnoila I.R., Yang X., Swain S.M., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. The Journal of Clinical Investigation 2003, 111(1):81-90.
72. Carlisle D.L., Hopkins T.M., Gaither-Davis A., Silhanek M.J., Luketich J.D., Christie N.A., et al. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respiratory Research 2004, 5:27.
73. Martinez-Garcia E., Irigoyen M., Anso E., Martinez-Irujo J.J., Rouzaut A. Recurrent exposure to nicotine differentiates human bronchial epithelial cells via epidermal growth factor receptor activation. Toxicology and Applied Pharmacology 2008, 228(3):334-342.
74. Zhang M., Wang H., Teng H., Shi J., Zhang Y. Expression of SHH signaling pathway components in the developing human lung. Histochemistry and Cell Biology 2010, 134(4):327-335.
75. Chuang P.T., Kawcak T., McMahon A.P. Feedback control of mammalian Hedgehog signaling by the Hedgehog-binding protein, Hip1, modulates Fgf signaling during branching morphogenesis of the lung. Genes & Development 2003, 17(3):342-347.
76. Shi W., Chen F., Cardoso W.V. Mechanisms of lung development: contribution to adult lung disease and relevance to chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2009, 6(7):558-563.
77. Dasari V., Gallup M., Lemjabbar H., Maltseva I., McNamara N. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"?. American Journal of Respiratory Cell and Molecular Biology 2006, 35(1):3-9.
78. Katoh Y., Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). International Journal of Molecular Medicine 2008, 22(3):271-275.
79. Sohal S.S., Reid D., Soltani A., Ward C., Weston S., Muller H.K., et al. Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respiratory Research 2011, 12:130.
80. Gorowiec M.R., Borthwick L.A., Parker S.M., Kirby J.A., Saretzki G.C., Fisher A.J. Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-beta1-dependent mechanism. Free Radical Biology & Medicine 2012, 52(6):1024-1032.
81. Amsellem V., Gary-Bobo G., Marcos E., Maitre B., Chaar V., Validire P., et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2011, 184(12):1358-1366.
82. Kumaki F., Kawai T., Hiroi S., Shinomiya N., Ozeki Y., Ferrans V.J., et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Human Pathology 2001, 32(2):188-195.
83. Lantuejoul S., Soria J.C., Morat L., Lorimier P., Moro-Sibilot D., Sabatier L., et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clinical Cancer Research 2005, 11(5):2074-2082.
84. Lantuejoul S., Soria J.C., Moro-Sibilot D., Morat L., Veyrenc S., Lorimier P., et al. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. British Journal of Cancer 2004, 90(6):1222-1229.
85. Sundar I.K., Mullapudi N., Yao H., Spivack S.D., Rahman I. Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics. Current Opinion in Pulmonary Medicine 2011, 17(4):279-285.
86. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics 2002, 3(6):415-428.
87. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., et al. DNA methylation markers and early recurrence in stage I lung cancer. The New England Journal of Medicine 2008, 358(11):1118-1128.
88. Sood A., Petersen H., Blanchette C.M., Meek P., Picchi M.A., Belinsky S.A., et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. American Journal of Respiratory and Critical Care Medicine 2010, 182(9):1098-1104.
89. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(20):11891-11896.
90. Suzuki M., Wada H., Yoshino M., Tian L., Shigematsu H., Suzuki H., et al. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Annals of Surgical Oncology 2010, 17(3):878-888.
91. Ito K., Ito M., Elliott W.M., Cosio B., Caramori G., Kon O.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. The New England Journal of Medicine 2005, 352(19):1967-1976.
92. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293(5535):1653-1657.
93. Vertino P.M., Spillare E.A., Harris C.C., Baylin S.B. Altered chromosomal methylation patterns accompany oncogene-induced transformation of human bronchial epithelial cells. Cancer Research 1993, 53(7):1684-1689.
94. Osada H., Tatematsu Y., Saito H., Yatabe Y., Mitsudomi T., Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International journal of cancer Journal international du cancer 2004, 112(1):26-32.
95. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004, 46(2):171-178.
96. Pottelberge G.R., Mestdagh P., Bracke K.R., Thas O., Durme Y.M., Joos G.F., et al. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2011, 183(7):898-906.
97. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(10):3903-3908.
98. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research 2004, 64(11):3753-3756.
99. Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R.N., et al. 21st-century hazards of smoking and benefits of cessation in the United States. The New England Journal of Medicine 2013, 368(4):341-350.
100. Young R.P., Hopkins R., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. European Respiratory Review: An Official Journal of the European Respiratory Society 2009, 18(114):222-232.
101. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin Use and reduced cancer-related mortality. New England Journal of Medicine 2012, 367(19):1792-1802.
102. Emberson J.R., Kearney P.M., Blackwell L., Newman C., Reith C., Bhala N., et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PloS One 2012, 7(1):e29849.
103. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England Journal of Medicine 2011, 365(5):395-409.
104. Tammemagi M.C., Katki H.A., Hocking W.G., Church T.R., Caporaso N., Kvale P.A., et al. Selection criteria for lung-cancer screening. The New England Journal of Medicine 2013, 368(8):728-736.
105. Rennard S.I., Fogarty C., Kelsen S., Long W., Ramsdell J., Allison J., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2007, 175(9):926-934.
106. Raviv S., Hawkins K.A., DeCamp M.M., Kalhan R. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. American Journal of Respiratory and Critical Care Medicine 2011, 183(9):1138-1146.
107. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339(6117):286-291.
108. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366(26):2443-2454.